The record
Every lens's verdict on every study. buy-below is the only price-falsifiable verdict — scored against the current close. watch / pass / too-hard are recorded but unscored: the question they answer is what would move them, not what to buy.
No buy-below verdict has been issued across 3 studies — 10 watch, 3 pass, 2 too-hard. The checklists have found durable, asset-rich businesses and judged all of them too expensive. An empty buy column is discipline showing its work, not indecision — the reasoning is the product.
| Study | Buffett | Munger | Pabrai | Li Lu | Claude |
|---|---|---|---|---|---|
| 4676Fuji Media Holdings¥3,996 · as of 2026-07-02 | watchunscored | passunscored | passunscored | too hardunscored | watchunscored |
| 4967Kobayashi Pharmaceutical¥5,505 · as of 2026-07-02 | watchbuy < ¥3,400 · now +62%unscored | watchbuy < ¥3,600 · now +53%unscored | watchbuy < ¥2,900 · now +90%unscored | watchunscored | passunscored |
| 7564Workman Co., Ltd.¥6,220 · as of 2026-07-02 | watchbuy < ¥4,100 · now +52%unscored | watchunscored | too hardunscored | watchbuy < ¥3,400 · now +83%unscored | watchbuy < ¥3,600 · now +73%unscored |
Prices are unadjusted TSE closes; as-of dates shown. A price that predates a study's stamp never renders a hit. Corporate actions restate buy-below thresholds at review time.